About antihemophilic factor + human recombinant
Plasma-derived factor VIII replacement
Used for
- Controls and prevents bleeding in hemophilia A
- Prevents bleeding during surgery in hemophilia A
Usual adult dose
Usually 10–50 IU/kg intravenously every 8–24 hours, depending on bleeding severity, factor VIII levels, and response.
Usual dose in children
Weight-based intravenous dosing, generally similar to adults; dose and frequency depend on bleeding severity, factor VIII levels, and response.
Common side effects
- Headache
- Fever or chills
- Injection-site discomfort
- Allergic reactions
Important warnings
- Koate-DVI is plasma-derived, not recombinant.
- Severe allergic reactions, including anaphylaxis, can occur.
- Factor VIII inhibitors may develop, reducing treatment effectiveness.
- Plasma-derived products carry a small residual infection transmission risk.
Pregnancy
Limited pregnancy data; use only when clearly needed.
Breastfeeding
Milk transfer and effects on breastfed infants are unknown; use requires weighing benefits and potential risks.
Interactions
- No well-established major drug interactions.
- Do not mix with other medicines in the same syringe.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.